What To Know
- “The acquisition of PQ Bypass is a seminal moment in Endologix's history, building upon our leadership in the treatment of abdominal aortic aneurysm to champion disruptive technologies for the treatment of vascular disease,” said Richard Mott, CEO and chairman, Endologix.
- With the acquisition of PQ Bypass, we believe the company is positioned to accelerate its leadership in the treatment of vascular disease, and we look forward to supporting continued growth.
April 13, 2021
Endologix LLC today announced it has completed the acquisition of PQ Bypass, Inc., a privately held medical technology company pioneering a first-of-its-kind technology that addresses an unmet need for new treatments for severe peripheral arterial disease (PAD).
PQ Bypass’ proprietary Detour platform for percutaneous femoral-popliteal bypass has been designated by the U.S. Food & Drug Administration as a Breakthrough Device. The Detour System consists of the TORUS stent graft and the PQ Crossing Device. The Detour System is currently being studied in a U.S. and European clinical trial, DETOUR2.
“The acquisition of PQ Bypass is a seminal moment in Endologix’s history, building upon our leadership in the treatment of abdominal aortic aneurysm to champion disruptive technologies for the treatment of vascular disease,” said Richard Mott, CEO and chairman, Endologix. “We intend to actively pursue new and innovative vascular technologies that are clinically relevant to surgeons, hospitals and patients, with a commitment to world-class medical education, clinical research and excellent procedural outcomes.”
Andrew ElBardissi, MD, partner at Deerfield Management stated, “We are excited about the progress that Endologix has made over the past year. With the acquisition of PQ Bypass, we believe the company is positioned to accelerate its leadership in the treatment of vascular disease, and we look forward to supporting continued growth.”
